New biosimilar brand drug - Simlandi (adalimumab-ryvk)

Simlandi (adalimumab-ryvk) - indicated for 1) moderate-severe rheumatoid arthritis in adult patients; 2) psoriatic arthritis in adult patients; 3) moderate-severe Crohn disease in adult and pediatric patients 6 years and older; and 4) various other indications.